MA40534B1 - Inhibiteurs de mk2 et leurs utilisations - Google Patents

Inhibiteurs de mk2 et leurs utilisations

Info

Publication number
MA40534B1
MA40534B1 MA40534A MA40534A MA40534B1 MA 40534 B1 MA40534 B1 MA 40534B1 MA 40534 A MA40534 A MA 40534A MA 40534 A MA40534 A MA 40534A MA 40534 B1 MA40534 B1 MA 40534B1
Authority
MA
Morocco
Prior art keywords
inhibitors
compositions
compounds
methods
relates
Prior art date
Application number
MA40534A
Other languages
English (en)
Other versions
MA40534A (fr
Inventor
Deqiang Niu
Joseph John Mcdonald
Russell C Petter
Juswinder Singh
Matthew David Alexander
Claudio Chuaqui
John Malona
Yike Ni
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MA40534A publication Critical patent/MA40534A/fr
Publication of MA40534B1 publication Critical patent/MA40534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des composés, leurs compositions et des méthodes pour les utiliser.
MA40534A 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations MA40534B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA40534A MA40534A (fr) 2016-03-24
MA40534B1 true MA40534B1 (fr) 2021-04-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40534A MA40534B1 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Country Status (30)

Country Link
US (5) US9458175B2 (fr)
EP (2) EP3193611B1 (fr)
JP (3) JP6556225B2 (fr)
KR (1) KR102457848B1 (fr)
CN (1) CN106998692B (fr)
AU (1) AU2015317741B2 (fr)
BR (1) BR112017005266B1 (fr)
CA (1) CA2961607C (fr)
CL (1) CL2017000576A1 (fr)
CO (1) CO2017003279A2 (fr)
CY (1) CY1124215T1 (fr)
DK (1) DK3193611T3 (fr)
EA (1) EA037299B1 (fr)
EC (1) ECSP17023281A (fr)
ES (1) ES2874561T3 (fr)
HR (1) HRP20210529T1 (fr)
HU (1) HUE054347T2 (fr)
IL (1) IL251051B (fr)
LT (1) LT3193611T (fr)
MA (1) MA40534B1 (fr)
MX (2) MX2017003359A (fr)
NZ (1) NZ730603A (fr)
PL (1) PL3193611T3 (fr)
PT (1) PT3193611T (fr)
RS (1) RS62017B1 (fr)
SA (1) SA517381115B1 (fr)
SG (2) SG11201701861RA (fr)
SI (1) SI3193611T1 (fr)
TW (1) TWI744217B (fr)
WO (1) WO2016044463A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
CA2961607C (fr) 2014-09-17 2023-03-28 Celgene Car Llc Inhibiteurs de mk2 et leurs utilisations
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
WO2018170201A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
WO2018170200A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2
MX2019010642A (es) 2017-03-16 2019-10-17 Celgene Car Llc Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
CN110678178B (zh) * 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
CA3171335A1 (fr) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Monotherapies et polytherapies avec des inhibiteurs de ulk1/2
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4079855A1 (fr) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Composé et procédé pour la prophylaxie et le traitement de la leucémie
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (fr) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Composés diazépino-thiéno-quinoxaline et leur utilisation en thérapie

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
WO1995026325A2 (fr) 1994-03-25 1995-10-05 Isotechnika Inc. Potentialisation de medicaments par deuteration_______________
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006514043A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
WO2005020921A2 (fr) 2003-08-29 2005-03-10 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
EP1849781A1 (fr) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Dérivés de 3-Amino-4-hydroxy pyrrolidine, procédé de fabrication et utilisation come medicaments
EP2223925A1 (fr) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AR067535A1 (es) 2007-07-16 2009-10-14 Novartis Ag Derivados de lactama tetraciclicos
WO2009055331A2 (fr) 2007-10-22 2009-04-30 Schering Corporation Dérivés hétérocycliques bicycliques et leurs procédés d'utilisation
MX360970B (es) 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (fr) * 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
EP2508511A1 (fr) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2511273B8 (fr) * 2011-04-15 2019-06-26 Hivih Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
WO2013124040A1 (fr) 2012-02-22 2013-08-29 Merck Patent Gmbh Milieu cristallin liquide
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (fr) * 2012-07-11 2015-12-02 Nimbus Iris Inc Inhibiteurs d'irak et leurs utilisations
MX2015003628A (es) * 2012-09-24 2016-11-08 Speede Claremont Sistema y metodo de acceso de datos y de eliminacion de datos controlados por remitente movil.
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
WO2015050957A2 (fr) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Traitements du lupus érythémateux systémique
WO2016032882A1 (fr) 2014-08-25 2016-03-03 Stc.Unm Inhibition de mk2 dans le traitement du cancer
CA2961607C (fr) 2014-09-17 2023-03-28 Celgene Car Llc Inhibiteurs de mk2 et leurs utilisations
RU2017128077A (ru) 2015-01-08 2019-02-08 Мори Матрикс, Инк. Составы, содержащие пептиды, ингибирующие мк2
WO2018170201A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
WO2018170200A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
JP2020514361A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
MX2019010642A (es) 2017-03-16 2019-10-17 Celgene Car Llc Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
EP3912981A1 (fr) 2021-11-24
US20210053984A1 (en) 2021-02-25
CY1124215T1 (el) 2022-05-27
NZ730603A (en) 2024-02-23
US9790235B2 (en) 2017-10-17
JP7375072B2 (ja) 2023-11-07
RS62017B1 (sr) 2021-07-30
SG11201701861RA (en) 2017-04-27
EA037299B1 (ru) 2021-03-05
TW201617351A (zh) 2016-05-16
SI3193611T1 (sl) 2021-08-31
CN106998692A (zh) 2017-08-01
US20170114073A1 (en) 2017-04-27
WO2016044463A3 (fr) 2016-09-01
MX2020005213A (es) 2020-08-20
EP3193611B1 (fr) 2021-03-24
KR20170063734A (ko) 2017-06-08
JP6556225B2 (ja) 2019-08-07
US9458175B2 (en) 2016-10-04
PL3193611T3 (pl) 2021-10-04
CA2961607A1 (fr) 2016-03-24
DK3193611T3 (da) 2021-05-10
US11584757B2 (en) 2023-02-21
HUE054347T2 (hu) 2021-08-30
HRP20210529T1 (hr) 2021-08-06
JP2017529367A (ja) 2017-10-05
TWI744217B (zh) 2021-11-01
ES2874561T3 (es) 2021-11-05
WO2016044463A2 (fr) 2016-03-24
CL2017000576A1 (es) 2017-12-01
MX2017003359A (es) 2017-11-22
CN106998692B (zh) 2020-09-08
EP3193611A4 (fr) 2018-02-28
AU2015317741A1 (en) 2017-04-20
AU2015317741B2 (en) 2020-01-16
MA40534A (fr) 2016-03-24
EP3193611A2 (fr) 2017-07-26
SG10201902326XA (en) 2019-04-29
PT3193611T (pt) 2021-05-28
LT3193611T (lt) 2021-08-25
US10253040B1 (en) 2019-04-09
ECSP17023281A (es) 2017-06-30
BR112017005266B1 (pt) 2022-11-01
US10577380B2 (en) 2020-03-03
IL251051A0 (en) 2017-04-30
CO2017003279A2 (es) 2017-09-29
CA2961607C (fr) 2023-03-28
JP2022078315A (ja) 2022-05-24
BR112017005266A2 (pt) 2017-12-12
SA517381115B1 (ar) 2021-03-09
US20160075720A1 (en) 2016-03-17
JP2019194236A (ja) 2019-11-07
EA201790380A1 (ru) 2017-08-31
US20190375762A1 (en) 2019-12-12
IL251051B (en) 2019-11-28
KR102457848B1 (ko) 2022-10-25

Similar Documents

Publication Publication Date Title
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500457A1 (en) New phenoxymethyl derivatives
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2018006148A (es) Inhibidores de cxcr2.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201790173A1 (ru) Антитела, связывающие axl
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX2019011496A (es) Composiciones de niraparib.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201790184A1 (ru) Пестицидные композиции
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MA39824A (fr) Composés azole amido-substitués